EUVIMEDEUVIMED entdecken
Crossref

Nimotuzumab-vinorelbine combination therapy versus other regimens in the treatment of pediatric diffuse intrinsic pontine glioma

Ayşe Özkan iD, Begül Yağcı Küpeli iD, Serhan Küpeli iD, Gülay Sezgin iD, İbrahim Bayram iD

Child's Nervous System · 2024

DOI: 10.1007/s00381-024-06329-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Child's Nervous System, 2024. Verfasst von Ayşe Özkan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Oncology and Pediatric Bone Marrow Transplantation Unit, Faculty of Medicine, Balcali Hospital, Çukurova University, Adana, T…. Hauptthemen laut MEDLINE: Brain Stem Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal, Humanized, Diffuse Intrinsic Pontine Glioma. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Pediatric diffuse intrinsic pontine glioma (DIPG) is a fatal disease associated with a median survival of < 1 year despite aggressive treatments. This retrospective study analyzed the treatment outcomes of patients aged < 18 years who were diagnosed with DIPG between 2012 and 2022 and who received different chemotherapy regimens. METHODS: After radiotherapy, patients with DIPG received nimotuzumab-vinorelbine combination or temozolomide-containing therapy. When nimotuzumab was unavailable, it was replaced by vincristine, etoposide, and carboplatin/cyclophosphamide (VECC). Temozolomide was administered as a single agent or a part of the combination chemotherapy comprising temozolomide, irinotecan, and bevacizumab. Furthermore, 1- and 3-year overall survival (OS), progression-free survival (PFS), and median OS and PFS were analyzed. RESULTS: The median age of 40 patients with DIPG was 97 ± 46.93 (23-213) months; the median follow-up time was 12 months. One and 3-year OS were 35.0% and 7.5%, respectively. Median OS was 12 months in all patients (n = 40), and it was 16, 10, and 11 months in those who received first-line nimotuzumab-vinorelbine combination (n = 13), temozolomide-based (n = 14), and VECC (n = 6) chemotherapy regimens, respectively (p = 0.360). One patient who received gefitinib survived for 16 months. Conversely, patients who never received radiotherapy and any antineoplastic medicamentous therapy (n = 6) had a median OS of 4 months. CONCLUSION: Nimotuzumab-vinorelbine combination therapy prolonged OS by 6 months compared with temozolomide-containing chemotherapy, although the difference was not statistically significant.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain Stem NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsAntibodies, Monoclonal, HumanizedDiffuse Intrinsic Pontine GliomaHumansFemaleChildMaleChild, PreschoolRetrospective StudiesAdolescentTemozolomideVinblastineInfantTreatment Outcome

Stichwörter der Autor:innen

Diffuse pontine gliomaMedicamentous therapyNimotuzumabPediatricSurvivalVinorelbine

Substanzen

Antibodies, Monoclonal, HumanizedTemozolomideVinblastinenimotuzumab

Autor:innen und Institutionen

  • Department of Pediatric Oncology and Pediatric Bone Marrow Transplantation Unit, Faculty of Medicine, Balcali Hospital, Çukurova University, Adana, Turkey. drayseozkan79@yahoo.com.tr.
  • Department of Pediatric Hematology and Oncology, Adana City Training and Research Hospital, University of Health Sciences, Adana, Turkey.
  • Department of Pediatric Oncology and Pediatric Bone Marrow Transplantation Unit, Faculty of Medicine, Balcali Hospital, Çukurova University, Adana, Turkey.

ORCID-Profile: Ayşe Özkan, Begül Yağcı Küpeli, Serhan Küpeli, Gülay Sezgin, İbrahim Bayram

Zitieren

APA

Özkan, A., Yağcı Küpeli, B., Küpeli, S., Sezgin, G., & Bayram, İ. (2024). Nimotuzumab-vinorelbine combination therapy versus other regimens in the treatment of pediatric diffuse intrinsic pontine glioma. Child's Nervous System. https://doi.org/10.1007/s00381-024-06329-4

Vancouver

Özkan A, Yağcı Küpeli B, Küpeli S, Sezgin G, Bayram İ. Nimotuzumab-vinorelbine combination therapy versus other regimens in the treatment of pediatric diffuse intrinsic pontine glioma. Child's Nervous System. 2024. doi:10.1007/s00381-024-06329-4

BibTeX
@article{zkan2024,
  author = {Özkan, Ayşe and Yağcı Küpeli, Begül and Küpeli, Serhan and Sezgin, Gülay and Bayram, İbrahim},
  title = {Nimotuzumab-vinorelbine combination therapy versus other regimens in the treatment of pediatric diffuse intrinsic pontine glioma},
  journal = {Child's Nervous System},
  year = {2024},
  doi = {10.1007/s00381-024-06329-4}
}
Kostenlos starten →